Mark Goodwin

Managing Director and Senior Equity Analyst at Leerink Partners

Marc Goodman is a Managing Director and Senior Equity Analyst at Leerink Partners, distinguished for his expertise in the healthcare sector with a focus on pharmaceuticals and biotechnology. He actively covers a broad array of companies including Avadel Pharmaceuticals, Warner Chilcott, Forest Labs, Auxilium, Cubist Pharma, Salix, Bausch Health Companies, and Assertio Therapeutics, earning a performance track record with an average return of 5.2% per rating and a 47% success rate across over 1,000 analyst calls. Ranked #1,898 out of 9,889 Wall Street analysts on TipRanks, he is recognized for notable high-return recommendations such as a 575% gain on Avadel Pharmaceuticals. Goodman has built his career as a specialist since at least 2010, with a reputation for analytical rigor and a history of covering both US and international markets; his professional credentials include appropriate FINRA registration and regulatory securities licenses.